Almeda Ventures Limited Partnership (AMDA) fair value: what the stock is really worth
As of Oct 9, 2026: fair value of Almeda Ventures Limited Partnership ILS 1.38, price ILS 2.49, upside -44.8%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range 0.8530 ILA – 6.07 ILA · fair‑value band 0.9605 ILA – 1.76 ILA · the 2.49 ILA price screens above the 1.38 ILA fair value. Dashed = 300-day average. As of Oct 3, 2026.
Follow Almeda Ventures Limited Partnership in your weekly email
Every Wednesday you see whether Almeda Ventures Limited Partnership is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Almeda Ventures Limited Partnership is a venture capital firm specializing in seed, start up, early venture and middle market investments. The firm seeks to invest in health technology with focus on public R&D partnership, medical devices, digital health and bio-convergence; life sciences research and development company.
Show more
Almeda Ventures Limited Partnership is a venture capital firm specializing in seed, start up, early venture and middle market investments. The firm seeks to invest in health technology with focus on public R&D partnership, medical devices, digital health and bio-convergence; life sciences research and development company. It prefers to invest in Israel, USA and Europe. Almeda Ventures Limited Partnership was founded in 2020 and is based in Tel Aviv, Israel.
Stock analysis
Almeda Ventures Limited Partnership (AMDA) currently trades at 2.49 ILA, while our model-based Fair Value estimate is 1.38 ILA, 44.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 1.62 ILA per share, and 0 of the 12 models we run sit above the 2.49 ILA price.
Bear case: the Earnings-Based group reads lowest at 0.8100 ILA, and 12 of the 12 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.9605 ILA (bear) to 1.76 ILA (bull), the price of 2.49 ILA sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Almeda Ventures Limited Partnership reported revenue of 87.7K ILA in FY2025 versus 1.6M ILA in FY2021, a compound −51.6%/yr. Reported net income was 1.9M ILA in FY2025, compounding +145.6%/yr from FY2021.
Key figures
Market cap 48.1M ILA · P/S ratio 4.50 · Dividend yield 3.8% · Net margin 92.8% · Return on equity 37.9% · Return on assets (EBIT) −4.0% · Operating margin 95.1% · Free cash flow −1.1M ILA.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 110% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −45%, AMDA screens richer than that median.
Fair Value models
Bear 0.9605 ILAFair Value 1.38 ILABull 1.76 ILA
Price 2.49 ILA · Upside -44.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.17/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: rate outside our plausibility band
Compare Almeda Ventures Limited Partnership with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks
Beats the industry median on 9/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−44.8% · Below median
Profitability
Return on equity (TTM)37.9% · Top 25%
Return on assets23.5% · Top 25%
Net margin (TTM)92.8% · Top 25%
Operating margin (TTM)95.1% · Top 25%
Growth and dividend
Revenue growth0.0% · Below median
Dividend yield (TTM)3.8% · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/B0.61× · Cheapest 25%
P/S (TTM)1.46× · Cheaper than median
EV/EBITDA1.6× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 41
PAST (return on equity)100· sector 11
HEALTH (low debt)0· sector 98
DIVIDEND (yield)75· sector 43
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Almeda Ventures Limited Partnership (AMDA) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 1.38 ILA versus a price of 2.49 ILA, about −45% upside (overvalued).
What is the fair value of AMDA?
Our model-based fair value for Almeda Ventures Limited Partnership is 1.38 ILA (as of Oct 3, 2026), built from audited fundamentals. The current price: 2.49 ILA.
What is the quality score of AMDA?
Almeda Ventures Limited Partnership has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Almeda Ventures Limited Partnership (AMDA)?
Our model-based price target is the fair value of 1.38 ILA (as of Oct 3, 2026) from 12 valuation models. Cautious scenario 0.9605 ILA, optimistic scenario 1.76 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Almeda Ventures Limited Partnership stock forecast for 2026?
Our models put fair value at 1.38 ILA, about −45% upside versus a price of 2.49 ILA (overvalued). Cautious scenario 0.9605 ILA, optimistic scenario 1.76 ILA. The calculation is refreshed regularly with new filings.
Does Almeda Ventures Limited Partnership pay a dividend?
Almeda Ventures Limited Partnership currently shows a dividend yield of about 3.77% relative to its recent price (as of Oct 3, 2026).
What is the intrinsic value of Almeda Ventures Limited Partnership (AMDA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Almeda Ventures Limited Partnership it is 1.38 ILA per share (as of Oct 3, 2026), against a price of 2.49 ILA. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is Almeda Ventures Limited Partnership stock overvalued or undervalued in 2026?
As of Oct 3, 2026, AMDA trades above its calculated fair value: price 2.49 ILA, fair value 1.38 ILA, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AMDA?
No. The price is what the market pays today (2.49 ILA); the fair value is what the company's own numbers justify (1.38 ILA). For Almeda Ventures Limited Partnership the two are 1.12 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Almeda Ventures Limited Partnership worth?
The market values Almeda Ventures Limited Partnership at about 48.1M ILA (market capitalisation, as of Oct 3, 2026). Per share that is 2.49 ILA; our models calculate a fair value of 1.38 ILA per share.
What do the bullish and bearish scenarios say about AMDA?
Our models span a range for Almeda Ventures Limited Partnership: cautious scenario 0.9605 ILA, base 1.38 ILA, optimistic 1.76 ILA per share (as of Oct 3, 2026, price 2.49 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Almeda Ventures Limited Partnership (AMDA)?
Balance-sheet figures for Almeda Ventures Limited Partnership (as of Oct 3, 2026): return on equity 37.9%. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is AMDA from its 52-week high?
Almeda Ventures Limited Partnership trades at 2.49 ILA, about 9% below its 52-week high of 2.75 ILA and 110% above the low of 1.19 ILA (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of 1.38 ILA is for.
Which stocks are comparable to Almeda Ventures Limited Partnership?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Almeda Ventures Limited Partnership stock attractive at the current price?
The data as of Oct 3, 2026: price 2.49 ILA, calculated fair value 1.38 ILA (−45%), Quality Score 59/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AMDA calculated?
We run Almeda Ventures Limited Partnership through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.38 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Almeda Ventures Limited Partnership itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Almeda Ventures Limited Partnership (AMDA)?
The closing price on Oct 9, 2026 was 2.49 ILA. Our model-based fair value is 1.38 ILA, about −45% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Almeda Ventures Limited Partnership right now?
The price sits above even our optimistic bull case (1.76 ILA). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (0.9605 ILA to 1.76 ILA) leaves room in how you read the outcome.
Key figures of Almeda Ventures Limited Partnership
How large is the market capitalisation of Almeda Ventures Limited Partnership (AMDA)?
The market capitalisation of Almeda Ventures Limited Partnership is 48.1M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Almeda Ventures Limited Partnership (AMDA)?
The price-to-sales ratio of Almeda Ventures Limited Partnership is 4.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Almeda Ventures Limited Partnership (AMDA)?
The dividend yield of Almeda Ventures Limited Partnership is 3.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Almeda Ventures Limited Partnership (AMDA)?
The net margin of Almeda Ventures Limited Partnership is 92.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Almeda Ventures Limited Partnership (AMDA)?
The return on equity (ROE) of Almeda Ventures Limited Partnership is 37.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Almeda Ventures Limited Partnership (AMDA)?
On an EBIT basis the return on assets of Almeda Ventures Limited Partnership is −4.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Almeda Ventures Limited Partnership (AMDA)?
The operating margin of Almeda Ventures Limited Partnership is 95.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Almeda Ventures Limited Partnership (AMDA) generate?
The free cash flow of Almeda Ventures Limited Partnership is −1.1M ILA (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Almeda Ventures Limited Partnership (AMDA) hold?
Almeda Ventures Limited Partnership holds more cash than debt, 78.0K ILA net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Almeda Ventures Limited Partnership in the live analysis
One click puts Almeda Ventures Limited Partnership on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
